{"id":"livalova","safety":{"commonSideEffects":[{"rate":null,"effect":"Muscle pain or myalgia"},{"rate":null,"effect":"Elevated liver enzymes"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Gastrointestinal disturbance"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pitavastatin is a selective and competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis. LivaloVA represents a next-generation formulation or derivative intended to improve lipid-lowering efficacy and potentially reduce cardiovascular events in patients with dyslipidemia. The drug works by decreasing hepatic cholesterol production, leading to upregulation of LDL receptors and enhanced clearance of LDL cholesterol from the bloodstream.","oneSentence":"LivaloVA is a pitavastatin analog designed to lower cholesterol by inhibiting HMG-CoA reductase with enhanced potency and cardiovascular benefits.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:19:06.772Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia and dyslipidemia"},{"name":"Cardiovascular risk reduction"}]},"trialDetails":[{"nctId":"NCT05331014","phase":"PHASE3","title":"To Evaluate the Efficacy and Safety in Patients With Dyslipidemia and Hypertension","status":"COMPLETED","sponsor":"JW Pharmaceutical","startDate":"2021-11-15","conditions":"Dyslipidemia, Hypertension","enrollment":155},{"nctId":"NCT05351840","phase":"PHASE1","title":"To Evaluate the Pharmacokinetic Interactions and Safety in Healthy Volunteers","status":"COMPLETED","sponsor":"JW Pharmaceutical","startDate":"2020-11-02","conditions":"Healthy","enrollment":31}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["JW0101+C2101","Period III"],"phase":"phase_3","status":"active","brandName":"LivaloVA","genericName":"LivaloVA","companyName":"JW Pharmaceutical","companyId":"jw-pharmaceutical","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LivaloVA is a pitavastatin analog designed to lower cholesterol by inhibiting HMG-CoA reductase with enhanced potency and cardiovascular benefits. Used for Hypercholesterolemia and dyslipidemia, Cardiovascular risk reduction.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}